Summary
Global Markets Direct’s, ‘Profectus BioSciences, Inc. - Product Pipeline Review - 2016’, provides an overview of the Profectus BioSciences, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Profectus BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Profectus BioSciences, Inc.
- The report provides overview of Profectus BioSciences, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Profectus BioSciences, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Profectus BioSciences, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Profectus BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Profectus BioSciences, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Profectus BioSciences, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Profectus BioSciences, Inc. Snapshot 7
Profectus BioSciences, Inc. Overview 7
Key Information 7
Key Facts 7
Profectus BioSciences, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Profectus BioSciences, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Profectus BioSciences, Inc. - Pipeline Products Glance 16
Profectus BioSciences, Inc. - Clinical Stage Pipeline Products 16
Phase I Products/Combination Treatment Modalities 16
Profectus BioSciences, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Profectus BioSciences, Inc. - Drug Profiles 19
(Ebola + Marburg) (monovalent) vaccine 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
(Ebola + Marburg) (trivalent) vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HIV [strain C1086] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HIV-1 vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IHV-001 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(nipah + hendra) vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
chikungunya vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
equine encephalitis vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
hepatitis B vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
hepatitis C vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
human papillomavirus (7-valent) vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
M-102.4 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
herpes simplex virus 2 vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Lassa fever vaccine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
respiratory syncytial virus vaccine 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Profectus BioSciences, Inc. - Pipeline Analysis 40
Profectus BioSciences, Inc. - Pipeline Products by Target 40
Profectus BioSciences, Inc. - Pipeline Products by Route of Administration 41
Profectus BioSciences, Inc. - Pipeline Products by Molecule Type 42
Profectus BioSciences, Inc. - Recent Pipeline Updates 43
Profectus BioSciences, Inc. - Dormant Projects 45
Profectus BioSciences, Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Profectus BioSciences, Inc., Key Information 7
Profectus BioSciences, Inc., Key Facts 7
Profectus BioSciences, Inc. - Pipeline by Indication, 2016 10
Profectus BioSciences, Inc. - Pipeline by Stage of Development, 2016 11
Profectus BioSciences, Inc. - Monotherapy Products in Pipeline, 2016 12
Profectus BioSciences, Inc. - Combination Treatment Modalities in Pipeline, 2016 13
Profectus BioSciences, Inc. - Partnered Products in Pipeline, 2016 14
Profectus BioSciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15
Profectus BioSciences, Inc. - Phase I, 2016 16
Profectus BioSciences, Inc. - Preclinical, 2016 17
Profectus BioSciences, Inc. - Discovery, 2016 18
Profectus BioSciences, Inc. - Pipeline by Target, 2016 40
Profectus BioSciences, Inc. - Pipeline by Route of Administration, 2016 41
Profectus BioSciences, Inc. - Pipeline by Molecule Type, 2016 42
Profectus BioSciences, Inc. - Recent Pipeline Updates, 2016 43
Profectus BioSciences, Inc. - Dormant Developmental Projects,2016 45
Profectus BioSciences, Inc., Other Locations 46
List of Figures
Profectus BioSciences, Inc. - Pipeline by Top 10 Indication, 2016 9
Profectus BioSciences, Inc. - Pipeline by Stage of Development, 2016 11
Profectus BioSciences, Inc. - Monotherapy Products in Pipeline, 2016 12
Profectus BioSciences, Inc. - Combination Treatment Modalities in Pipeline, 2016 13
Profectus BioSciences, Inc. - Pipeline by Top 10 Target, 2016 40
Profectus BioSciences, Inc. - Pipeline by Top 10 Molecule Type, 2016 42
